Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study

Daniel P O'Brien, Anthony McDonald, Peter Callan, Mike Robson, N Deborah Friedman, Andrew Hughes, Ian Holten, Aaron Walton, Eugene Athan, Daniel P O'Brien, Anthony McDonald, Peter Callan, Mike Robson, N Deborah Friedman, Andrew Hughes, Ian Holten, Aaron Walton, Eugene Athan

Abstract

Background: The World Health Organization currently recommends combined streptomycin and rifampicin antibiotic treatment as first-line therapy for Mycobacterium ulcerans infections. Alternatives are needed when these are not tolerated or accepted by patients, contraindicated, or neither accessible nor affordable. Despite in vitro effectiveness, clinical evidence for fluoroquinolone antibiotic use against Mycobacterium ulcerans is lacking. We describe outcomes and tolerability of fluoroquinolone-containing antibiotic regimens for Mycobacterium ulcerans in south-eastern Australia.

Methodology/principal findings: Analysis was performed of prospectively collected data including all primary Mycobacterium ulcerans infections treated at Barwon Health between 1998 and 2010. Medical treatment involved antibiotic use for more than 7 days; surgical treatment involved surgical excision of a lesion. Treatment success was defined as complete lesion healing without recurrence at 12 months follow-up. A complication was defined as an adverse event attributed to an antibiotic that required its cessation. A total of 133 patients with 137 lesions were studied. Median age was 62 years (range 3-94 years). 47 (34%) had surgical treatment alone, and 90 (66%) had combined surgical and medical treatment. Rifampicin and ciprofloxacin comprised 61% and rifampicin and clarithromycin 23% of first-line antibiotic regimens. 13/47 (30%) treated with surgery alone failed treatment compared to 0/90 (0%) of those treated with combination medical and surgical treatment (p<0.0001). There was no difference in treatment success rate for antibiotic combinations containing a fluoroquinolone (61/61 cases; 100%) compared with those not containing a fluoroquinolone (29/29 cases; 100%). Complication rates were similar between ciprofloxacin and rifampicin (31%) and rifampicin and clarithromycin (33%) regimens (OR 0.89, 95% CI 0.27-2.99). Paradoxical reactions during treatment were observed in 8 (9%) of antibiotic treated cases.

Conclusions: Antibiotics combined with surgery may significantly increase treatment success for Mycobacterium ulcerans infections, and fluoroquinolone combined with rifampicin-containing antibiotic regimens can provide an effective and safe oral treatment option.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1. Type of treatment for initial…
Figure 1. Type of treatment for initial M. ulcerans lesions.
Figure 2. Proportion of individual antibiotics ceased…
Figure 2. Proportion of individual antibiotics ceased over time due to complications.

References

    1. van der Werf TS, van der Graaf WT, Tappero JW, Asiedu K. Mycobacterium ulcerans infection. Lancet. 1999;Sep 18;354(9183):1013–8.
    1. Sizaire V, Nackers F, Comte E, Portaels F. Mycobacterium ulcerans infection: control, diagnosis, and treatment. The Lancet infectious diseases. 2006;May;6(5):288–96.
    1. Johnson PD. Should antibiotics be given for Buruli ulcer? Lancet. 2010;Feb 20;375(9715):618–9.
    1. Chauty A, Ardant MF, Marsollier L, Pluschke G, Landier J, et al. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis. 2011;Jan;52(1):94–6.
    1. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet. 2010;Feb 20;375(9715):664–72.
    1. O'Brien DP, Hughes AJ, Cheng AC, Henry MJ, Callan P, et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. The Medical journal of Australia. 2007;Jan 15;186(2):58–61.
    1. Chauty A, Ardant MF, Adeye A, Euverte H, Guedenon A, et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrobial agents and chemotherapy. 2007;Nov;51(11):4029–35.
    1. Ji B, Lefrancois S, Robert J, Chauffour A, Truffot C, Jarlier V. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrobial agents and chemotherapy. 2006;Jun;50(6):1921–6.
    1. Thangaraj HS, Adjei O, Allen BW, Portaels F, Evans MR, et al. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. The Journal of antimicrobial chemotherapy. 2000;45(2):231–3.
    1. Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, et al. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrobial agents and chemotherapy. 2001;45(11):3109–12.
    1. World Health Orgainisation. Buruli Ulcer. [cited 2011 3rd June]; Available from: .
    1. O'Brien DP, Athan E, Hughes A, Johnson PD. Successful treatment of Mycobacterium ulcerans osteomyelitis with minor surgical debridement and prolonged rifampicin and ciprofloxacin therapy: a case report. Journal of medical case reports. 2008;2:123.
    1. Dhople AM, Namba K. In vitro activity of sitafloxacin (DU-6859a) alone, or in combination with rifampicin, against Mycobacterium ulcerans. The Journal of antimicrobial chemotherapy. 2002;Nov;50(5):727–9.
    1. Dhople AM, Namba K. Activities of sitafloxacin (DU-6859a), either singly or in combination with rifampin, against Mycobacterium ulcerans infection in mice. J Chemother. 2003;15(1):47–52.
    1. Saito HIN. Antibacterial activities of new fluoroquinolones against Mycobacterium Ulcerans. Journal of Antimicrobial Chemotherapy. 2001;47,(suppl 2)(May):Abstract P53.
    1. Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrobial agents and chemotherapy. 1992;May;36(5):993–6.
    1. Fong IW, Ledbetter WH, Vandenbroucke AC, Simbul M, Rahm V. Ciprofloxacin concentrations in bone and muscle after oral dosing. Antimicrobial agents and chemotherapy. 1986;Mar;29(3):405–8.
    1. Ji B, Chauffour A, Robert J, Lefrancois S, Jarlier V. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrobial agents and chemotherapy. 2007;Oct;51(10):3737–9.
    1. O'Brien DP, Robson ME, Callan PP, McDonald AH. “Paradoxical” immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. The Medical journal of Australia. 2009;Nov 16;191(10):564–6.
    1. Phanzu DM, Ablordey A, Imposo DB, Lefevre L, Mahema RL, et al. Short report: edematous Mycobacterium ulcerans infection (Buruli ulcer) on the face: a case report. The American journal of tropical medicine and hygiene. 2007;Dec;77(6):1099–102.
    1. Gordon CL, Buntine JA, Hayman JA, Lavender CJ, Fyfe JA, et al. All-oral antibiotic treatment for buruli ulcer: a report of four patients. PLoS neglected tropical diseases. 2010;4(11):e770.
    1. Ross BC, Marino L, Oppedisano F, Edwards R, Robins-Browne RM, et al. Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection. J Clin Microbiol. 1997;Jul;35(7):1696–700.
    1. Guarner J, Bartlett J, Whitney EA, Raghunathan PL, Stienstra Y, et al. Histopathologic features of Mycobacterium ulcerans infection. Emerging infectious diseases. 2003;Jun;9(6):651–6.
    1. Kennedy N, Fox R, Kisyombe GM, Saruni AO, Uiso LO, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. The American review of respiratory disease. 1993;Dec;148(6 Pt 1):1547–51.
    1. Gumbo T, Louie A, Deziel MR, Drusano G. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrobial agents and chemotherapy. 2005;Aug;49(8):3178–81.
    1. Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis. 1997;Nov;25(5):1213–21.
    1. Rallis E, Koumantaki-Mathioudaki E. Treatment of Mycobacterium marinum cutaneous infections. Expert opinion on pharmacotherapy. 2007;Dec;8(17):2965–78.
    1. Chan-Tompkins NH. Toxic effects and drug interactions of antimycobacterial therapy. Clinics in dermatology. 1995;May–Jun;13(3):223–33.
    1. Ruf MT, Chauty A, Adeye A, Ardant MF, Koussemou H, et al. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? PLoS neglected tropical diseases. 2011;Aug;5(8):e1252.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다